Page last updated: 2024-11-07

hypothiocyanite ion

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

hypothiocyanite ion: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

hypothiocyanous acid : A sulfur oxoacid that is sulfenic acid in which the hydrogen attached to the sulfur has been replaced by a cyano group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID124984
MeSH IDM0063259
PubMed CID124985
CHEBI ID133907
MeSH IDM0063259

Synonyms (20)

Synonym
hypothiocyanite ion
oscn-
63296-34-4
n84cz7t0oy ,
unii-n84cz7t0oy
DTXSID40979382
(thiocyanato)oxidanide
hydroxy thiocyanate
hypothiocyanite
cyanosulfoxylate
nitrilomethane-so-thioperoxol
hypothiocyanous acid
CHEBI:133907
(hydroxysulfanyl)formonitrile
hypocyanous acid
cyanosulfoxylic acid
64253-39-0
DTXSID20276285
oscn-hypothiocyanite ion
n,6-didehydro-3,6-dihydro-3-methyl-adenosine

Research Excerpts

Overview

The hypothiocyanite ion (OSCN(-)) is a normal component of human saliva.

ExcerptReferenceRelevance
"The hypothiocyanite ion (OSCN(-)) is a normal component of human saliva. "( Peroxidase-thiocyanate-peroxide antibacterial system does not damage DNA.
Mansson-Rahemtulla, B; Pruitt, KM; White, WE, 1983
)
0.82

Toxicity

ExcerptReferenceRelevance
" However, as OSCN- is a highly-reactive oxidizing agent, its possible toxic effect on human cells was studied using gingival fibroblasts as target cells."( The protective effect of peroxidase and thiocyanate against hydrogen peroxide toxicity assessed by the uptake of [3H]-thymidine by human gingival fibroblasts cultured in vitro.
Larjava, H; Tenovuo, J, 1984
)
0.27
" The toxic agent was also formed in the absence of lactoperoxidase in a reaction between hypothiocyanite and hydrogen peroxide."( Bactericidal and cytotoxic effects of hypothiocyanite-hydrogen peroxide mixtures.
Carlsson, J; Edlund, MB; Hänström, L, 1984
)
0.27

Bioavailability

ExcerptReferenceRelevance
" Decreased NO• bioavailability is an early and critical event in atherogenesis, and HOSCN-mediated damage to eNOS may contribute to smoking-associated disease."( The smoking-associated oxidant hypothiocyanous acid induces endothelial nitric oxide synthase dysfunction.
Davies, MJ; Kwan, J; Suryo Rahmanto, A; Talib, J; Witting, PK, 2014
)
0.4

Dosage Studied

ExcerptRelevanceReference
" The dosage of OSCN- consists in a well referenced colorimetric method but no procedure is described for the determination of OI- ions."( Development of a colorimetric method for the dosage of OI- anions and I2 in aqueous media.
Bafort, F; Barthelemy, JP; Jijakli, HM; Parisi, O; Perraudin, JP, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
oxidising agentA substance that removes electrons from another reactant in a redox reaction.
antiviral agentA substance that destroys or inhibits replication of viruses.
antibacterial agentA substance (or active part thereof) that kills or slows the growth of bacteria.
antifungal agentAn antimicrobial agent that destroys fungi by suppressing their ability to grow or reproduce.
rat metaboliteAny mammalian metabolite produced during a metabolic reaction in rat (Rattus norvegicus).
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
one-carbon compoundAn organic molecular entity containing a single carbon atom (C1).
sulfur oxoacid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
Events associated with phagocytolytic activity of PMN cells213
Immune System91482
Innate Immune System41475
ROS and RNS production in phagocytes1237

Research

Studies (141)

TimeframeStudies, This Drug (%)All Drugs %
pre-199021 (14.89)18.7374
1990's31 (21.99)18.2507
2000's25 (17.73)29.6817
2010's50 (35.46)24.3611
2020's14 (9.93)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.01 (24.57)
Research Supply Index4.65 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (7.22%)5.53%
Trials0 (0.00%)5.53%
Reviews5 (5.15%)6.00%
Reviews6 (12.77%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other85 (87.63%)84.16%
Other41 (87.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized, Double Blind, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics After Single Ascending Doses or Multiple Ascending Doses of OSCN-, bLF or ALX-009 in Healthy Male and CF and Non-CF Bronchiectasis Patients [NCT02598999]Phase 192 participants (Actual)Interventional2015-11-30Terminated(stopped due to Financial issues)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]